M&A / Deals EverSea Medicines to acquire Hasten Biopharmaceuticals Pharmaceutical Business ReviewThe acquisition aims to enhance Everest Medicines' presence and commercial capabilities across key regional markets.M&A / DealsRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaceutical Business Review The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Jeito Capital secures over $1.2bn for new biopharma investmentsNext: 23andMe study explains variable results with obesity drugs Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
